Kardigan (KARD)
Develops cardiovascular therapies through biologically defined, data-enabled clinical trials.
$21.82
At close+2.22 (+11.33%)
In millions of USD, except per-share figures
| In millions | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|
| Cost of revenue | 0 | 2 |
| Gross profit | 0 | −2 |
| 59 | 73 | |
| Research & development | 45 | 55 |
| 14 | 18 | |
| General & administrative | 14 | 0 |
| Operating income | −59 | −75 |
| 3 | −41 | |
| Interest income | 3 | 3 |
| Income before tax | −56 | −116 |
| Net income from continuing operations | −56 | −116 |
| Net income | −56 | −116 |
| EPS, basic | −$0.90 | −$1.24 |
| EPS, diluted | −$0.90 | −$1.24 |
| Weighted average shares, basic | 62 | 93 |
| Weighted average shares, diluted | 62 | 93 |
| EBITDA | −57 | −73 |
| Depreciation & amortization | 2 | 2 |
| EBIT | −59 | −75 |